APPL1 and prostate carcinoma: The Appl-1, Sortilin, and Syndecan-1 biomarker panel addresses critical diagnostic challenges in prostate cancer pathology by enhancing the accuracy of detection and reproducibility of Gleason grading and ISUP group assignment.